Incomplete Revascularization in the Long Term

Original Title: Long-Term Outcome of Incomplete Revascularization after Percutaneous Coronary Intervention in SCAAR (Swedish Coronary Angiography and Angioplasty Registry). Reference: Kristina Hambraeus et al. J Am Coll Cardiol Intv. 2016;9(3):207-215.

 

The aim of this study was to describe the evolution of patients with multivessel disease undergoing PCI with incomplete revascularization, and its probable association to death, repeat revascularization and MI in the long term.

Between 2006 and 2010 23342 patients with multivessel disease were identified in the SCAAR registry (Swedish Coronary Angiography and Angioplasty Registry). Incomplete revascularization was defined as any vessel with a lesion larger than 60% irrigating at least 10% of the myocardium.

Patients with incomplete revascularization (n = 15,165) were older, with more extensive coronary disease and often had STEMI at presentation, compared to those with complete revascularization (n = 8,177).

At one year, all cause mortality, AMI and repeat revascularization rates were higher among the incomplete revascularization patients, compared to those with complete revascularization (7.1% vs 3.8%, 10.4% vs 6.0% and 20.5% vs 8.5%, respectively).

After propensity score matching, the adjusted risk at one year for the composite of death, MI or revascularization was significantly higher for the incomplete revascularization group. (HR 2.12 CI 95% 1.98 to 2.28; p < 0.0001).

The adjusted risk of death and the combination of death/MI also resulted higher for the incomplete revascularization group with 1.29 (CI 95% 1.12 to 1.49; p=0.0005) and 1.42 (CI 95% 1.30 to 1.56; p<0.0001), respectively.

Conclusion
Incomplete revascularization at discharge in patients with multivessel disease undergoing PCI is associated with a high risk of adverse cardiac events at one year.

Editorial Comment
So far, the evidence is conflictive and generally indirect. Even though this study provides important data, is limited by its retrospective character and by the fact that it was carried out in different populations, which required several adjustments for researchers to be able to compare. Clearly, in almost all studies, patients with incomplete revascularization are always at higher risk, and their treatment was determined by the impossibility to receive a complete revascularization, rather than by choice.

More articles by this author

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

QFR vs. FFR: Is Coronary Revascularization Deferral Safe? Results from a FAVOR III Sub-Analysis

In cases of intermediate coronary lesions, functional assessment is recommended to aid the decision-making process regarding revascularization. There are several tools currently used to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...